Kawasaki disease match trial: identifying kids who need treatment
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Fever for at least 3 days (either measured or felt by touch)
- At least one fever measured at home or in the emergency room that is 100.4 degrees Fahrenheit (38.0 Celsius) or higher
- At least one classic sign of Kawasaki disease, like rash, red eyes, changes in mouth or throat, red or swollen hands or feet, or a swollen neck gland (1.5 cm or larger)
- For babies under 6 months old: fever for 7 or more days qualifies even if they do not have classic signs
- Must need a blood draw or IV as part of regular medical care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at children with Kawasaki disease, a condition that causes inflammation in blood vessels. The goal is to learn more about how it affects kids in Europe and North India.
This study looks at Kawasaki disease that gets complicated by a serious immune reaction called macrophage activation syndrome (MAS). It aims to better understand and treat this complication in children.
This study tests whether anakinra, a medicine that calms inflammation, is just as good as the standard treatment for Kawasaki disease in children. The goal is to reduce fever and prevent heart problems.
This study uses artificial intelligence to look at chest X-rays to help doctors find Kawasaki disease earlier. It may lead to faster treatment and better outcomes for children.
This study uses heart imaging to better understand Kawasaki disease. It may help doctors assess heart health in affected children and teenagers.
This trial tests whether adding a new medication (firsekibart) to the standard treatment for Kawasaki disease (immunoglobulin) works better than standard treatment alone. It aims to reduce the risk of heart problems and improve recovery.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.